USPTO serial 99434165
PANTHER
Reviewed by CopyMark Law Group
Status 653
- Filing date
- Status date
- Registration date
- —
- Examiner
- SHINER, MARK W
- Law office
- TMEG LAW OFFICE 105
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with PANTHER?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jessica L. Rothstein
Jessica L. Rothstein Goodwin Procter LLP620 Eighth AvenueNew York, NY 10018United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical products in the nature of implantable solid drug formulations for the treatment of cancer; Pharmaceutical products and drug delivery platforms in the nature of compounds that facilitate delivery of pharmaceuticals for the prevention, diagnosis, and treatment of cancer; Pharmaceutical products and drug delivery platforms in the nature of compounds that facilitate localized delivery of pharmaceuticals for the sustained treatment of cancer; Pharmaceutical products in the nature of implantable solid drug formulations that improve therapeutic efficacy, minimize systemic toxicity, and expand treatment options, all related to cancer | ACTIVE | Jun 19, 2017 |
| 010 | Implantable solid drug formulations to treat cancer; Drug delivery system in the nature of a system that delivers an implantable solid drug formulation to treat cancer; Drug delivery system in the nature of a system to prevent, diagnose, and treat cancer; Drug delivery system that facilitates delivery of pharmaceuticals that improve therapeutic efficacy, minimize systemic toxicity, and expand treatment options, all related to cancer | ACTIVE | Jun 19, 2017 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 21, 2026 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Aug 21, 2026 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Aug 21, 2026 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Aug 2, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 2, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 2, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 14, 2026 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| May 14, 2026 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Mar 4, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 4, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 4, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 3, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 3, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 3, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Feb 26, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 9, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 9, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 9, 2025 | NWAP | NEW APPLICATION ENTERED | — |